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Introduction: Small fiber neuropathies (SFN) are associated with a reduction in qual-
ity of life. In adults, epidermal nerve fiber density (END) analysis is recommended for
the diagnosis of SFN. In children, END assessment is not often performed. We ana-
lyzed small nerve fiber innervation to elucidate the potential diagnostic role of skin
biopsies in young patients with pain.
Methods: Epidermal nerve fiber density and sudomotor neurite density (SND) were
assessed in skin biopsies from 26 patients aged 7 to 20 years (15 female patients)
with unexplained chronic pain. The results were compared with clinical data.
Results: Epidermal nerve fiber density was abnormal in 50% and borderline in 35% of
patients. An underlying medical condition was found in 42% of patients, including
metabolic, autoimmune, and genetic disorders.
Discussion: Reduction of epidermal nerve fibers can be associated with treatable
conditions. Therefore, the analysis of END in children with pain may help to uncover
a possible cause and guide potential treatment options.
K E YWORD S
epidermal nerve fiber density, neuropathic pain, skin biopsy, small fiber, small fiber
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Abbreviations: AOI, area of interest; END, epidermal nerve density; NCS, nerve conduction study; PBS, phosphate-buffered saline; PGP 9.5, protein gene product 9.5; QST, quantitative sensory
testing; SFN, small fiber neuropathy; SG, sweat glands; SND, sudomotor neurite density; TRP, transient receptor potential.
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1 | INTRODUCTION
Small fiber neuropathy (SFN) is known to cause neuropathic pain in
adults with distal distribution and autonomic symptoms, leading to a
reduction in quality of life.1-3 Small fiber neuropathy is characterized by
damage to small unmyelinated C and thinly myelinated A δ nerve fibers.
The underlying etiology of SFN is diverse and includes metabolic, toxic,
autoimmune, or genetic disorders. The etiology of approximately 30%
cases remains unknown.2,4-10 Recent studies have found that the clinical
spectrum of SFN is broader than initially suspected. In addition, general-
ized pain symptoms can be associated with small fiber degeneration,
which makes the clinical diagnosis even more challenging.7,9,11-14
In children, the underlying etiology and symptoms of SFNmight be
different from those in adults. Diabetes mellitus is one of the most com-
mon etiologies of SFN in adults but is less common in younger
patients.15-17 Juvenile and adult patients with Fabry disease often pre-
sentwith severe neuropathic pain, making SFN the initial symptom.18,19
Other genetic causes such as channelopathies and hereditary sensory
neuropathies are associated with SFN.10 Small fiber toxicity is
described in both children and adults who have received chemother-
apy.20 In young patients with SFN, autoimmune diseases might often
be the underlying cause, and appropriate therapies can reduce pain
symptoms in a subset of patients.21-23 However, SFN associated with
other conditions, such as infectious, nutritional, or hereditary diseases,
might occur in young patients with pain. In addition, small fiber pathol-
ogy and reduction in epidermal nerve density (END) have been
described in patients with fibromyalgia syndrome who present with
chronic widespread pain.24,25
Diagnosing SFN remains a challenge. Small nerve fibers cannot be
evaluated with routine tests, such as nerve conduction studies (NCS),
which detect only impairment of the fast conducting A-α (motor NCS)
and A-β (sensory NCS) fibers. Special electrophysiological tests, such
as quantitative sensory testing (QST), are required to evaluate small
fiber function. Normative values are available for children and young
adolescents but are dependent on the patient's cooperation.26 In addi-
tion, QST is not available in all pediatric clinics.
F IGURE 1 END and SND in proximal skin biopsies of the nonpain group. Analysis of sweat gland innervation with antibodies against PGP 9.5
in 50-μm sections (A). END showed a negative correlation with age (B). SND showed no correlation with age (C) and no correlation with END (D).
Scale bar = 50 μm. END, epidermal nerve density; PGP 9.5, protein gene product 9.5; SND, sudomotor neurite density
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Analyzing epidermal nerve fibers in small skin punch biopsies is a
recommended technique to allow a diagnosis of SFN in adult
patients.27 The punch biopsy procedure is minimally invasive and can
be performed under local anesthesia. Several studies have analyzed
END in large groups of healthy individuals, and reference values are
available for female and male patients in different age groups, demon-
strating a decrease in END in older individuals.27-29 However, these
studies did not include individuals younger than 20 years of age,30,31
so interpretation of END and diagnoses of SFN in younger patients is
challenging. Reports describing the use of skin biopsies for diagnosing
SFN in children are not as numerous. 16,21-23 Only a few studies have
analyzed END in healthy children, and reference values are not
available.30-32
In patients with SFN, autonomic disturbances occur frequently
because C fibers mediate not only pain and temperature but also
autonomic function.2,33 The involvement of autonomic nerve fibers
can be evaluated by analyzing sudomotor fibers in skin biopsies.34-38
Morphometric analyses of sweat gland innervation have been
described in adults, but recommended standard values are not avail-
able.39 Sudomotor abnormalities in children with small fiber dysfunc-
tion are frequent, but morphometric analysis of sweat gland
innervation in skin biopsies has not been performed in a large cohort
of children.16,21
In this study, we analyzed epidermal and sudomotor nerve fiber
innervation to elucidate the potential diagnostic role of skin biopsies
in children and adolescents with unexplained chronic pain.
2 | MATERIALS AND METHODS
2.1 | Ethics statement
This work was approved by the ethical committee of the University of
Giessen. Written informed consent was obtained from all patients or
from their parents (AZ 85/16).
2.2 | Patients
Young patients with unexplained chronic pain were seen and exam-
ined at pediatric clinics in Germany and Belgium. All patients who




Pain symptoms 26/26 (100)
Chronic progression, disease duration >1 year 18/25 (72)
Pain on numerical rating scale, >6/10 6/7 (86)
Diffuse distribution, legs, eyes, abdomen, back,
head, joints
7/26 (27)
Distal distribution, predominant in distal legs and
hands
19/26 (73)
Pain quality 20/26 (77)
Burning 6/20 (30)








Cold temperature 4/18 (22)
Warm temperature 2/18 (11)
Physical activity 7/18 (39)
Post infectious 2/18 (11)
Touching or pressure on trigger points 3/18 (17)
Others: stress, rest, fatigue 3/18 (17)
Sleep disturbances 11/21 (52)
Pain medication 17/22 (77)
Autonomic dysfunction 18/26 (69)
Digestion problems: nausea, constipation,
dysphagia, abdominal pain, feeding problems
13/18 (72)
Incontinence: fecal and micturition 5/18 (28)
Hot flushes, dizziness, orthostatic problems 6/18 (33)
Hyperhidrosis, nocturnal sweating 3/18 (17)
Restless leg syndrome 8/26 (31)
Erythromelalgia 4/17 (24)






Diabetes mellitus type 1 1/26 (4)
Autoimmune 3/26 (12)
TRPA1 c.145A > G; p.Asn49Asp 1/26 (4)
1q21.1 microdeletion 1/26 (4)
Lambert Eaton myasthenic syndrome with 1/26 (4)
Xp11.22-p11.23 duplication [51]







CMT1 (PMP22 mutation) 1/26 (4)
CMT2 2/26 (8)
Abbreviations: CMT, Charcot–Marie–Tooth disease; TRPA1, transient
receptor potential A1.
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underwent a skin biopsy from January 2015 to May 2019 were
included in the study. In all patients, extensive diagnostic testing was
performed, including laboratory investigations, genetic testing, and
NCS. Clinical data were collected retrospectively.
For controls (nonpain group), proximal skin biopsies were ana-
lyzed that had been obtained from 15 children and teenagers aged
6 months to 19 years who underwent a muscle biopsy for diagnostic
reasons (eg, cardioskeletal myopathy or storage disorder). Per-
forming skin biopsies in healthy children for determining standard
values was deemed not suitable for ethical reasons. All patients
undergoing a muscle biopsy from January 2017 to May 2019 and/or
their legal guardians gave consent to excise a small longitudinal sam-
ple of skin after the incision for the muscle biopsy. None of the
patients had a history of pain or complained of any clinical symptoms
suggestive of small fiber pathology. Moreover, all of these patients
had normal NCS and did not have any disorders known to be associ-
ated with SFN.
2.3 | Analysis of skin biopsies
Three-millimeter skin punch biopsies were taken distally, 10 cm
above the lateral malleolus of the leg in all patients with pain. In the
nonpain group, proximal skin biopsies were obtained from the lateral
thigh. The skin biopsy analysis was performed according to
European Federation of Neurological Societies guidelines.27 Skin
samples were fixed with Zamboni fixative (2% paraformaldehyde,
15% picric acid, phosphate-buffered saline [PBS]) for at least
48 hours, washed in PBS, transferred to 10% sucrose, and stored at
−80C freezer until use. From each biopsy, 50-μm thick frozen
sections were stained by using a free-floating protocol. Primary anti-
body anti–protein gene product (PGP 9.5, 1:1000; Zytomed, Berlin,
Germany) was incubated overnight at room temperature in a PBS
solution containing 0.1% Triton X-100, 0.1% Tween 20, and 0.1%
bovine serum albumin. The goat anti–rabbit Alexa Fluor 488 second-
ary antibody (1:1000; Thermo Fisher Scientific, Waltham, Massachu-
setts) was incubated for 3 hours at room temperature. Sections were
mounted with 40,6-diamidino-2-phenylindole (Fluorshield; Abcam,
Cambridge, Massachusetts).
All samples were examined with a Leica Microsystems (Wetzlar,
Germany) DM 2000 fluorescence microscope at ×400 with a Leica
DFC450C camera. Morphological analysis was performed in Leica
Application-Suite Version 4.7.1 and Fiji ImageJ (version 1.51n;
https://fiji.sc/). The investigator (J.G.) was blinded to the specimen
category during the morphologic evaluation of biopsies.
2.4 | Quantification of END
Intraepidermal nerve fibers crossing the dermal-epidermal junction
were counted according to published counting recommendations.27
At minimum, six sections were analyzed from each biopsy. Epider-
mal nerve fiber density was assessed as the density of the total
length of the epidermis (nerve fibers/mm). Epidermal nerve density
was considered abnormal when it was lower than the fifth percen-
tile (mean of 6.1 in male patients and 8.4 in female patients) and
borderline when it was between the fifth percentile and the median
(mean of 10.9 in male patients and 13.5 in female patients) com-
pared to recommended reference values for 20 to 29-year-old
individuals.32
TABLE 2 Proximal skin biopsy analysis of nonpain group
Patient Sex Age at biopsy, y END, fibers/mm SND (%) Etiology
NP1 M 19 11.9 44 Mitochondrial disorder
NP14 AG 16 20.1 ND Juvenile idiopathic arthritis overlap syndrome
NP2 G 12 13 36 Cardiomyopathy
NP9 B 10 12.4 ND Congenital myopathy
NP13 B 10 20.6 45 Becker muscular dystrophy
NP7 B 8 17.5 52 Congenital myopathy
NP4 G 7 29.5 46 Segawa disease
NP12 B 7 15.8 45 Duchenne muscular dystrophy
NP6 G 7 12.8 43 Congenital myopathy
NP10 G 5 17.4 46 Dermatomyositis
NP3 B 5 26.2 41 Motor development disorder
NP8 G 4 34.1 49 Cardiomyopathy
NP11 B 4 21.9 49 Cardiomyopathy
NP15 G 1 29 ND Mental retardation + muscular hypotonia
NP5 IG 0.6 21.1 57 Cardiomyopathy
Abbreviations: AG, adolescent girl; B, boy; END, epidermal nerve fiber density; G, girl; IG, infant girl; M, man; ND, not done; NP, nonpain patient; SND,
sudomotor neurite density.
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2.5 | Quantitation of sudomotor neurite density
Sudomotor nerve density (SND) was analyzed in 50-μm-thick sections
stained for the panaxonal marker PGP 9.5 by using a manual quantita-
tion method reported by Gibbons et al.37 Eccrine sweat glands
(SG) were captured by using both in-focus and out-of-focus images to
mark the area of interest (AOI) with Leica Application-Suite 4.7.0 at
×200. Sweat glands with a size <300 μm and SGs directly associated
with hair follicles were excluded. At minimum, four SGs were ana-
lyzed. ImageJ was used to create a grid of circles (10 μm in diameter
with a horizontal space of 50 μm and a vertical space one of 25 μm)
that was merged with the in-focus image taken from the SG. Protein
gene product 9.5-positive fibers crossing the circles were counted and
divided by all circles, both within the AOI (Figure 1A). Sudomotor
nerve density was expressed as percentage grid intercepts. No recom-
mendations for normal values for SND are available. Therefore, we
referred to Gibbons et al,37 who reported abnormal SND in adults
with diabetes mellitus type 2 (SND 20.8% ± 12.2%) and normal SND
in healthy individuals (SND 40.8% ± 12.8%) and considered SND as
abnormal when it was ≤28% and as borderline when it was 29%
to 40%.
2.6 | Statistical analysis
Statistical analyses were performed in Prism 7 (GraphPad Software,
San Diego, California) and R 3.6.0 (R Foundation for Statistical
Computing, Vienna, Austria. http://www.R-project.org/). Initially, a
Shapiro–Wilk test was performed on every variable of the data
(age, END and SND for pain and nonpain as well as “progression of
pain”) for normal distribution of the data. We then used the Spear-
man rank-order correlation to compute the relationship between
the variables and modeled the relationships between the variables
via linear regression. We further used the Bonferroni correction to
adjust the α-level from α = .05 down to α = .017 because we used
END from the pain group three times in the Spearman's rank-order
correlation. Two-sample t tests were used for estimations of dif-
fuse and distal pain means of END. The values are given as mean
and SD.
3 | RESULTS
3.1 | Clinical data of patients with pain
The patients with pain symptoms (n = 26) were aged 7 to 20 years
(14.2 ± 3.9), with 58% female patients. The delay of diagnosis from
onset of symptoms was, on average, 4 years. Most patients reported
chronic distal pain triggered by various factors, including cold temper-
ature and physical activity. An underlying medical condition that was
assumed to be causally related to the patient's pain was found in 42%
of patients, including metabolic, autoimmune, and genetic diseases
(Table 1, Table S1).
3.2 | Analysis of END and SND in proximal
biopsies from nonpain individuals
Proximal skin biopsies taken from nonpain participants showed a
mean END of 20.22 fibers/mm (11.9–34.1). The highest number was
F IGURE 2 END in distal skin biopsies of the pain group. Analysis of
ENDwith antibodies against PGP 9.5 in 50-μm sections. Patient 25with
normal ENDdistribution (A), and patient 20with severe reduction (B).
Distribution of END in the pain patients (C). END, epidermal nerve
density; PGP 9.5, protein gene product 9.5. Scale bars = 50 μm
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detected in a 4-year-old girl with 34.1 fibers/mm, and END showed a
negative correlation with age (Spearman's ρ = 0.65; P = 0.008;
Figure 1B, Table 2). Analysis of SG innervation revealed a mean SND
of 46% (36%–57%). Sudomotor neurite density showed no correlation
with age (Spearman's ρ = −0.56; P = 0.05) or END (Spearman's
ρ = 0.47; P = 0.12; Figure 1C,D; Table 2).
3.3 | Analysis of END and SND in patients
with pain
Patients with pain showed a mean END of 7.2 ± 3.9, varying from 0.7
to 17.6 fibers/mm. Epidermal nerve fiber density was abnormal in
50% and borderline in 35% of patients (Figure 2A-C, Table 3). Epider-
mal nerve density in samples with abnormal and borderline END was
6.17 ± 2.7 fibers/mm. Sudomotor neurite density could be analyzed in
20 patients. The mean value was 31.35% ± 10.05% (20%–58%) and
was abnormal in 55% and borderline in 30% of patients (Table 3). Spe-
arman's rank correlation analysis of SND and END showed no
correlation (Spearman's ρ = 0.34; P =0.14).
3.4 | Comparison of clinical data with END and
SND in patients with pain
In only four patients with pain was END normal: one patient (P19)
with hereditary spastic paraplegia (Strümpell Lorrain Syndrome) and
three patients (P21, P24, P25) with pain of unknown underlying dis-
ease (Table 3, Table S1). The disease progression did not correlate
with END or SND (Spearman's ρ = −0.40; P = 0.09). In addition, END
in patients with distal pain (73%, 6.9 fibers/mm, 0.7–12.9) did not sig-
nificantly differ from END in patients with generalized and diffuse
TABLE 3 Distal skin biopsy analysis of patients with pain
END SND
Patient Sex Progression of pain, y Age at biopsy, y Fibers/mm Level of reduction % Level of reduction
P20 G 5 20 4.8 Abnormal 27 Abnormal
P24 B 2 19 12.9 None ND ND
P13 B 2 19 7.9 Borderline 36 Borderline
P6 G 4 19 5.4 Abnormal 21 Abnormal
P15 G 1 18 2.8 Abnormal ND ND
P22 IG 0.5 17 2.4 Abnormal ND ND
P1 G 5 17 6.6 Abnormal 26 Abnormal
P5 G 3 17 6.8 Abnormal 24 Abnormal
P12 IB 0.25 17 8.1 Borderline 33 Borderline
P4 B 1 16 6.3 Borderline 28 Abnormal
P23 B 2 16 5.9 Abnormal 51 None
P14 IB 0.25 16 7.1 Borderline 26 Abnormal
P3 G 5 15 2.1 Abnormal ND ND
P16 G 2 15 4.7 Abnormal 33 Borderline
P18 AG 13 15 0.7 Abnormal 36 Borderline
P21 B NR 15 17.6 None 46 None
P8 B 8 14 5.3 Abnormal 24 Abnormal
P10 G 2 12 6.1 Borderline ND ND
P25 G 2 12 13.8 None 58 None
P17 IG 0.5 11 9.4 Borderline 31 Borderline
P19 IB 0.25 10 12 None 32 Borderline
P2 B 4 9 8.9 Borderline 27 Abnormal
P26 B 4 9 7.3 Borderline 23 Abnormal
P9 G 5 8 9.4 Borderline ND ND
P11 G 4.5 8 3.9 Abnormal 20 Abnormal
P7 G 3.5 7 8 Abnormal 25 Abnormal
Abbreviations: AG, adolescent girl; B, boy; END, epidermal nerve fiber density; IB, infant boy; IG, infant girl; G, girl; M, man; ND, not done; NR, not
reported; P, patient with pain; SND, sudomotor neurite density.
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pain symptoms (27%, eight fibers/mm, 2.1–17.6; P = 0.6). Epidermal
nerve density was abnormal in 63% and borderline in 37% of patients
with restless leg syndrome, and SND was abnormal in 75%. In all four
patients with erythromelalgia, END and SND were abnormal. Suffi-
cient numbers of SGs were available for analysis in only 50% of
patients reporting autonomic symptoms. Sudomotor neurite density
was abnormal in 64% and borderline in 31% of patients (Table 3). In
one patient with normal END (P19), a borderline SND was observed.
4 | DISCUSSION
Analyses of the skin biopsies showed an abnormal END in 50% of our
patients, confirming the diagnosis of SFN. The distribution of age and
sex was in line with other studies showing that very young children
are less affected.16,22
The present study has some limitations. Because clinical data
were analyzed retrospectively, pain detection questionnaires for
standardized classification of pain symptoms and autonomic function
tests were not available, and inclusion and exclusion criteria were
not specifically defined. Moreover, the number of skin biopsies ana-
lyzed in total as well as skin biopsies with adequate number of SGs
was rather small, and normal age-matched controls were not
available.
The analysis of proximal skin biopsies of nonpain children who
underwent a muscle and skin biopsy for diagnosing a muscular disor-
der confirmed a negative correlation of END with age.30,31 In our
study, the END of a 16-year-old adolescent girl was in the normal
range of reported data showing higher values in proximal compared
with distal biopsies.28,30,31,40 However, from these individual cases, it
cannot be determined whether END was affected by their underlying
disease. These findings in a small cohort of nonpain children highlight
the requirement for age-related standard values in younger patients
because of the age-dependent decrease in END during childhood and
adolescence.
Because we used 20- to 29-year old individuals as reference
values, the prevalence of SFN in the young patients with pain might
have been underestimated.
Single studies have previously described SFN and END reduction
in young patients with pain symptoms. Only a few children with pain
showed a severely reduced END consistent with the findings in our
study.16,21-23,41 In our cohort, the degree of END did not correlate
with pain distribution or pain progression. Epidermal nerve fiber den-
sity can correlate with disease progression but mainly in conditions
that are less frequent in younger patients, such as amyloid neuropathy
and diabetic neuropathy.42-44
The underlying etiology of SFN is heterogeneous but can be
determined in most adult patients. Most common are metabolic dis-
eases such as prediabetes, diabetes mellitus and glucose intolerance,
autoimmune diseases, sodium channel gene mutations, toxic, coeliac
disease, and vitamin B12 deficiency.
2,4-7,45 In children, SFN can occur
in genetic disorders including Fabry disease, hereditary sensory
autonomic neuropathy-1, and channel mutations and additionally can
affect children with immune-mediated, metabolic, or endocrine
disorders.10,46
In our study, the diagnosis of SFN elicited additional clinical test-
ing and led to the discovery of the presumed underlying etiology in
42% of patients. This included metabolic, hereditary, and autoimmune
etiologies. One patient with diabetes mellitus type 1 reported con-
stant neuropathic pain and was first misdiagnosed as psychosomatic.
A skin biopsy with severely reduced END confirmed the diagnosis of
SFN. Abnormal END in young pain patients with diabetes has also
been reported in other studies.16,21 Although erythromelalgia was
been diagnosed in 24% of the patients, genetic testing did not reveal
any known pathogenic mutations in the SCN9A gene.47,48 Mutations
in SCN9A, which codes for a voltage gated sodium channel (Nav1.7),
are associated with erythromelalgia, which is characterized by epi-
sodic neuropathic pain particularly triggered by warm temperature.
The frequency of SCN9A mutations in juvenile SFN should be
assessed in a larger cohort. A rare pathogenic mutation in the nocicep-
tor TRPA1 (transient receptor potential A1) was found in one patient.
This patient had early onset of pain symptoms at 3.5 years of age that
were triggered by cold temperature. One patient with such a mutation
in whom QST was normal and skin biopsy was not performed was
previously reported.49 However, the finding of abnormal END is in
line with other studies describing END reduction in erythromelalgia
conditions.50
In some patients in our study, laboratory test results provided evi-
dence of an autoimmune mediated disease. This is in line with other
studies postulating autoimmune diseases as a major cause of SFN in
children, with a benefical clinical effect of immunotherapies.21,51 In
addition, infections can trigger autoimmune neuropathies, and SFN is
described in postinfectious conditions.21,23 This was also seen in our
patients. One patient in our study with Lambert Eaton myasthenic
syndrome with duplication at Xp11.22-p11.23 reported predominant
distal pain triggered by cold temperature.52 The Xp11.2 duplication
might have contributed to the susceptibility of developing an autoim-
mune disorder because it contains FOXP3, which codes for a tran-
scription factor expressed by regulatory T cells.53 The pain
disappeared completely after immunosuppressive treatment. In addi-
tion, three patients with hereditary Charcot–Marie–Tooth disease
who reported unusually strong pain showed abnormal END. However,
painful neuropathies can be associated with an impairment in both
small and large nerve fibers.54,55
Analysis of SND as a variable to determine the density of auto-
nomic nerve fibers might be helpful, especially when testing for
sudomotor function, such as quantitative sudomotor axon reflex test,
is not available. However, the analysis of SND in skin biopsies is time
consuming and, therefore, difficult to use in routine diagnostics.37,39
In addition, an adequate number of SGs cannot be obtained in every
skin biopsy. In our study, 64% of patients with autonomic disturbance
showed an SND reduction. These results underscore the involvement
of SND and autonomic dysfunction in young patients with SFN. There
was no significant correlation between END and SND, in contrast to
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adults with diabetic SFN.37 A possible explanation could be the small
number of biopsies in which SND was analyzed. In one patient with
normal END, a borderline SND was observed, indicating that reduc-
tion in SND can occur earlier than reduction of END.36 In the nonpain
group, the mean SND of 46% is in line with other studies that have
analyzed healthy adults.37
In summary, our study demonstrates abnormal END in 50% of
young patients with chronic unexplained pain and describes patholog-
ical SG innervation in young patients with autonomic symptoms.
These findings support the requirement for skin biopsies as a diagnos-
tic tool in a subset of young patients with a pain syndrome and can
help uncover an underlying disease that may be causally related and
improve clinical care. Additional studies to determine age-related ref-
erence values in healthy children and to analyze larger cohorts of
young pain patients are required.
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